Novo Nordisk staying the course
Pharmaceutical giant showing small but steady gains
Novo Nordisk finished this year’s second quarter better profit-wise than it had expected. The company finished with a before tax profit of close to 9 billion kroner, just a bit higher than the 8.9 billion kroner it had projected. The company’s pretax profits for the first half of 2014 stand at 17.3 billion kroner, compared to 16.5 billion kroner for the same period last year.
´The success of two products – Levemir and Victoza – was instrumental in driving growth during the first half of the year.
The company also said that the US launch of its product Tresiba is progressing faster than expected. Novo Nordisk had previously announced that Tresiba would not be ready to start the stateside approval process until mid-2015. It now says that Tresiba could be considered for approval as early as the first quarter of 2015.
Novo Nordisk’s research and development sector has also shown positive growth in the first 6 months of the the year, posting a return of 6.2 billion kroner, nearly 900 million kroner more than in the first half of 2013.
The company said that it expects its numbers to remain steady for the rest of 2014.